WO2024254518A3 - Compositions of lipid delivery particles and method of use thereof - Google Patents

Compositions of lipid delivery particles and method of use thereof Download PDF

Info

Publication number
WO2024254518A3
WO2024254518A3 PCT/US2024/033099 US2024033099W WO2024254518A3 WO 2024254518 A3 WO2024254518 A3 WO 2024254518A3 US 2024033099 W US2024033099 W US 2024033099W WO 2024254518 A3 WO2024254518 A3 WO 2024254518A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
delivery particles
lipid delivery
delivery
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033099
Other languages
French (fr)
Other versions
WO2024254518A2 (en
Inventor
Dave PAJEROWSKI
Peter CABECEIRAS
Jeffrey L. Lee
Yi Yu
Karol BUDZIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nvelop Therapeutics Inc
Original Assignee
Nvelop Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nvelop Therapeutics Inc filed Critical Nvelop Therapeutics Inc
Publication of WO2024254518A2 publication Critical patent/WO2024254518A2/en
Publication of WO2024254518A3 publication Critical patent/WO2024254518A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to lipid delivery particles for delivery of payloads across cell membrane into the target cell. The present disclosure relates to lipid delivery particles comprising a lipid membrane on the external side and a chimeric protein in the core comprising a transmembrane domain, a heterologous payload, and a cleavable linker cleavable by protease expressed in the target cells. The systems and methods described herein provide for: the ability to produce the lipid delivery particles and the ability to delivery payloads such as proteins and small molecules into the target cells.
PCT/US2024/033099 2023-06-07 2024-06-07 Compositions of lipid delivery particles and method of use thereof Ceased WO2024254518A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471691P 2023-06-07 2023-06-07
US63/471,691 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254518A2 WO2024254518A2 (en) 2024-12-12
WO2024254518A3 true WO2024254518A3 (en) 2025-03-06

Family

ID=93796415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033099 Ceased WO2024254518A2 (en) 2023-06-07 2024-06-07 Compositions of lipid delivery particles and method of use thereof

Country Status (1)

Country Link
WO (1) WO2024254518A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196386A1 (en) * 2006-02-21 2007-08-23 Vu Halong N Stable retrovirus and methods of use
US20200308234A1 (en) * 2019-03-29 2020-10-01 Trustees Of Boston University Chimeric antigen receptor (car) modulation
WO2021113772A1 (en) * 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Particle delivery systems
US20220193223A1 (en) * 2014-04-23 2022-06-23 Modernatx, Inc. Nucleic acid vaccines
US20220259617A1 (en) * 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196386A1 (en) * 2006-02-21 2007-08-23 Vu Halong N Stable retrovirus and methods of use
US20220193223A1 (en) * 2014-04-23 2022-06-23 Modernatx, Inc. Nucleic acid vaccines
US20200308234A1 (en) * 2019-03-29 2020-10-01 Trustees Of Boston University Chimeric antigen receptor (car) modulation
US20220259617A1 (en) * 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021113772A1 (en) * 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Particle delivery systems

Also Published As

Publication number Publication date
WO2024254518A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Jaquinod et al. A proteomics dissection of Arabidopsis thaliana vacuoles isolated from cell culture
WO2008148519A3 (en) Mammalian expression vector with a highly efficient secretory signal sequence
WO2008140582A3 (en) Production of anti-microbial peptides
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
PL1966240T3 (en) Lactoferrin peptides useful as cell-penetrating peptides
WO2002098365A3 (en) Conditioned cell culture media and uses thereof
WO2007092161A3 (en) A direct cellular energy delivery system
AU2022257050A1 (en) Lipid nanoparticle compositions
WO2009134808A3 (en) Supercharged proteins for cell penetration
WO2006028704A8 (en) Compositions containing functionalized carbon materials
WO2007084364A3 (en) Improved il-12 for expression in mammalian cells
PT1251835E (en) Closure of bacterial ghosts
WO2011129462A3 (en) A YEAST EXTRACT CONTAINING γ-Glu-X OR γ-Glu-X-Gly AND A METHOD FOR PRODUCING THE SAME
WO2010061187A3 (en) Method for the transformation of plant cell mitochondria
WO2007137267A3 (en) Protein production using eukaryotic cell lines
CN103421834A (en) Method for expressing foreign protein with bacillus subtilis
WO2024254518A3 (en) Compositions of lipid delivery particles and method of use thereof
MXPA05012336A (en) Process of producing a plastid-targeted protein in plant cells.
WO2008126783A1 (en) Method for producing dipeptide
WO2021026506A3 (en) Aminoacyl-trna synthetases and cell lines for site-specific incorporation of unnatural amino acids
WO2009125999A3 (en) Human host cell for producing recombinant proteins with high quality and quantity
Lin Energetics of membrane transport in protoplasts
WO2005001099A3 (en) Protein expression system
WO2004085463A3 (en) Methods of unnatural amino acid incorporation in proteins in mammalian cells
Lazdunski et al. Insertion and translocation of proteins into and through membranes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820174

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE